Becoming a leading global biotech company ranked in the top 25 by 2030

A global biotech company with a rich and diverse heritage

Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, biotech company Aurobindo Pharma was born of a vision.

The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry, India. In addition to being the market leader in Semi-Synthetic Penicillin, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Antibiotics.

Through cost effective manufacturing capabilities and several loyal customers, the company also entered the high margin specialty generic formulations segment. oday Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products.

150 Countries

Benefiting from our medicines

Aurobindo’s formulation business is systematically organised with a focused team for key international markets.

Leveraging its large manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, Aurobindo achieved revenues of USD 3.3 billion in FY 2020-2021. Aurobindo’s 11 units for APIs and intermediates, and 15 units (10 in India, 3 in USA, 1 in Brazil, and 1 in Portugal) for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.

3.3 Billion

Revenue (2020-2021)

Biotech Company

Aurobindo Pharma’s Evolution

Aurobindo Pharma’s Evolution

  • Successful innovation in process chemistry
  • Cost competitive manufacturing
  • Large and diversified product portfolio
  • Global leadership in anti-infectives
  • Largest generic portfolio in Antiretroviral drugs (ARVs)
Biotech Company

Aurobindo Pharma’s Evolution

Aurobindo Pharma’s Evolution

  • Scale, Diversity and Leadership
  • Operational Excellence
  • Service Delivery
  • Patient Focus
Biotech Company

Robust research and development

Robust research and development

With one of the largest R&D facilities in India, Aurobindo Pharma has five research centres spread over 16,000 square meters. It also has 3 R&D centres in the USA. The biotech company employs over 1700+ scientists & analysts in-house with expertise in product development for ensuring quick turnaround times leading up to dossier submissions.

Latest News

CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar
Press Release

31 January 25

CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar

Read More
CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)
Press Release

21 December 24

CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)

Read More
CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar
Press Release

13 December 24

CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar

Read More
EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad
Press Release

12 November 24

EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad

Read More
CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Press Release

15 March 24

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar

Read More
Auro Peptides completes US FDA inspection with zero observations
Press Release

17 February 24

Auro Peptides completes US FDA inspection with zero observations

Read More
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Press Release

17 January 24

CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India

Read More
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Press Release

20 November 23

CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector

Read More
CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis
Press Release

10 July 23

CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis

Read More